Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels

Table 5

Comparison of quality of life.

	Physical functioning		Cognitive function		Role functioning		Social functioning		Emotional functioning
	Before treatment	One year after treatment	Before treatment	One year after treatment	Before treatment	One year after treatment	Before treatment	One year after treatment	Before treatment	One year after treatment
Control group (n = 65)	64.26 ± 5.97	77.69 ± 7.51	62.54 ± 5.53	76.84 ± 6.54	61.25 ± 5.23	78.64 ± 6.02	63.48 ± 6.08	80.14 ± 6.87	67.58 ± 6.31	81.54 ± 5.69
Combination group (n = 76)	65.04 ± 6.28	85.36 ± 7.33	62.78 ± 5.39	84.26 ± 6.45	61.87 ± 5.34	86.48 ± 6.69	64.03 ± 6.22	87.64 ± 7.18	68.04 ± 6.72	87.15 ± 6.13
t	0.7520	6.1239	0.2604	6.7656	0.6938	7.2619	0.5288	6.3067	0.4167	5.5983
	0.4533	<0.0001	0.7949	<0.0001	0.4889	<0.0001	0.5977	<0.0001	0.6775	<0.0001